Efficacy of a Novel Mitochondrial-Derived Peptide in a Porcine Model of Myocardial Ischemia/Reperfusion Injury.
Sharp. Thomas E TE; Gong. Zhenwei Z; Scarborough. Amy A; Goetzman. Eric S ES; Ali. Murtuza J MJ; Spaletra. Pablo P; Lefer. David J DJ; Muzumdar. Radhika H RH; Goodchild. Traci T TT
Key Findings
- HNG (2 mg/kg) reduced infarct size in a 60‑minute pig heart‑attack model
- The protective effect disappeared when ischemia time was extended
- Results confirm humanin’s cardioprotective potential in a large‑animal model but highlight dose‑timing limits
Practical Outcomes
- For now, there’s no ready‑to‑use protocol for biohackers. The data hint that early, appropriately dosed humanin could aid heart health, but more human‑focused research is needed before trying it yourself.
Summary
A study in pigs showed that a humanin‑like peptide (S14G‑humanin, 2 mg/kg) can shrink heart damage after a short (60‑minute) heart attack, but the same dose didn’t help when the blockage lasted longer. This suggests the peptide might protect the heart, but the right dose and timing aren’t clear yet.
Abstract
With the complexities that surround myocardial ischemia/reperfusion (MI/R) injury, therapies adjunctive to reperfusion that elicit beneficial pleiotropic effects and do not overlap with standard of care are necessary. This study found that the mitochondrial-derived peptide S14G-humanin (HNG) (2 mg/kg), an analogue of humanin, reduced infarct size in a large animal model of MI/R. However, when ischemic time was increased, the infarct-sparing effects were abolished with the same dose of HNG. Thus, although the 60-min MI/R study showed that HNG cardioprotection translates beyond small animal models, further studies are needed to optimize HNG therapy for longer, more patient-relevant periods of cardiac ischemia.
Study Information
pubmed
2020
2020-06-17T00:00:00.000Z
10.1016/j.jacbts.2020.04.015
21
62